Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Clinical Evidence Requirements For AI Must Be Based On Purpose, EU Expert Group Says

Executive Summary

EU guidance on clinical evidence requirements for medical device software does not yet include AI-specific information. An expert group explains how regulators can determine how much evidence is needed for AI-based devices and why common standards should be utilized.

You may also be interested in...

How Can The EU Get Clinical Evaluations For High-Risk Devices Right?

The new EU medtech regulations were developed as a reaction to unsafe products reaching patients; yet implementing new rules on clinical evidence has been anything but smooth. An expert from the BioMed Alliance tells Medtech Insight how this challenge can be addressed.

Why Manufacturers Face A ‘Phenomenal Challenge’ In Navigating EU AI Act Regulatory Maze

The European Commission’s proposed Artificial Intelligence Act has undergone some adaptations over the past year, but concerns remain around its impact on the medtech sector. In this interview, Philips’ Koen Cobbaert outlines the current situation and challenges.

EU Regulating AI ‘Like A Microwave’ When Focus Should Be Its Ability To Cook

Concerns are mounting over how the EU’s AI Act will impact the medtech sector. Now, a computer science expert has argued that the proposed regulation is fundamentally flawed in its approach, because it puts the focus on the AI product instead of its output.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts